TP53 and breast cancer: The evidence that breast cancer, and in particular its early-onset form, is the most common type of tumor in female patients with LFS provides a rationale for the germline analysis of TP53. Breast cancer was observed in 79% of female LFS patients in a French population with median age at disease onset at 33 years29.